 
 Brain Mechanisms of Reducing Polysubstance Use 
Following a Novel Body -mind Intervention  
Protocol Number: 03212020 
National Clinical Trial (NCT) Identified Number:  [STUDY_ID_REMOVED]  
Principal Investigator : Yi-Yuan Tang, Ph.D.  
Sponsor: Texas Tech  University  
Grant Title: Brain Mechanisms of Reducing Polysubstance Use Following a Novel 
Body -mind Intervention  
Grant Number: R61AT010138  
Funded by :  National Center for Complementary and Integrative Health  
Version Number:  v.1.1 
2020-03-21 
 
Summary of Changes  
Version  Date  
1.0 2019-02-27 
1.1 2020 -03-21 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  Involving Humans  CONFIDENTIALITY STATEMENT  
This document is confidential communication. Acceptance of this document constitutes agreement by the 
recipient that no unpublished information contained herein will be published or disclosed without prior 
approval  of the Principal Investigator  or other participating study leadership and as consistent with the 
NIH terms of award.  
 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 1020  21 March 20 20 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  Involving Humans  Table of Contents  
STATEMENT OF COMPLIANCE  ................................ ................................ ................................ .............................  1 
INVESTIGATOR’S SIGNATURE  ................................ ................................ ................................ ..............................  2 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ...............................  3 
1.1 Synopsis  ................................ ................................ ................................ ................................ ................  3 
1.2 Schema  ................................ ................................ ................................ ................................ .................  3 
1.3 Schedule of Activities  ................................ ................................ ................................ ..........................  5 
2 INTRODUCTION  ................................ ................................ ................................ ................................ ............  6 
2.1 Study Rationale  ................................ ................................ ................................ ................................ .... 6 
2.2 Background  ................................ ................................ ................................ ................................ ...........  6 
2.3 Risk/Benefit Assessment  ................................ ................................ ................................ ....................  6 
2.3.1  Known Potential Risks  ................................ ................................ ................................ ..... 6 
2.3.2  Known Potential Benefits  ................................ ................................ ................................  7 
2.3.3  Assessment of Potential Risks and Benefits  ................................ ................................  7 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ................................ ................  8 
4 STUDY DESIGN  ................................ ................................ ................................ ................................ .............  8 
4.1 Overall Design  ................................ ................................ ................................ ................................ ...... 8 
4.2 Scientific Rationale for Study Design  ................................ ................................ ................................  8 
4.3 Justification for Intervention  ................................ ................................ ................................ ...............  9 
4.4 End-of-Study Definition  ................................ ................................ ................................ .......................  9 
5 STUDY POPULATION  ................................ ................................ ................................ ................................ .. 9 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................................ .. 9 
5.2 Exclusion Criteria  ................................ ................................ ................................ ................................ . 9 
5.3 Lifestyle Considerations  ................................ ................................ ................................ ......................  9 
5.4 Screen Failures  ................................ ................................ ................................ ................................ .... 9 
5.5 Strategies for Recruitment and Retention  ................................ ................................ ......................  10 
6 STUDY INTERVENTION(S) OR EXPERIMENTAL MANIPULATION(S)  ................................ ............  10 
6.1 Study Intervention(s) or Experimental Manipulation(s) Administration  ................................ ...... 10 
6.1.1  Study Intervention or Experimental Manipulation Description  ................................ . 10 
6.1.2  Administration and/or Dosing  ................................ ................................ .......................  11 
6.2 Fidelity  ................................ ................................ ................................ ................................ .................  11 
6.2.1  Interventionist Training and Tracking  ................................ ................................ ..........  11 
6.3 Measures to Minimize Bias: Randomization and Blinding  ................................ ...........................  11 
6.4 Study Intervention/Experimental Manipulation Adherence  ................................ ..........................  11 
6.5 Concomitant Therapy  ................................ ................................ ................................ ........................  12 
6.5.1  Rescue Therapy  ................................ ................................ ................................ .............  12 
7 STUDY INTERVENTION/EXPERIMENTAL MANIPULATION DISCONTINUATION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL  ................................ ................................ .........................  12 
7.1 Discontinuation of Study Intervention/Experimental Manipulation  ................................ .............  12 
7.2 Participant Discontinuation/Withdrawal from the Study  ................................ ...............................  12 
7.3 Lost to Follow -Up ................................ ................................ ................................ ...............................  12 
8 STUDY ASSESSMENTS AND PROCEDURES  ................................ ................................ ......................  13 
8.1 Endpoint and Other Non -Safety Assessments  ................................ ................................ ..............  13 
8.2 Safety Assessments  ................................ ................................ ................................ ..........................  13 
8.3 Adverse Events and Serious Adverse Events  ................................ ................................ ...............  13 
8.3.1  Definition of Adverse Events  ................................ ................................ ........................  13 
8.3.2  Definition of Serious Adverse Events  ................................ ................................ ..........  14 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 1020  21 March 20 20 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  Involving Humans  8.3.3  Classification of an Adverse Event  ................................ ................................ ..............  14 
8.3.4  Time Period and Frequency for Event Assessment and Follow -Up .......................  15 
8.3.5  Adverse Event Reporting  ................................ ................................ ..............................  15 
8.3.6  Serious Adverse Event Reporting  ................................ ................................ ...............  15 
8.3.7  Reporting Events to Participants  ................................ ................................ .................  15 
8.3.8  Events of Special Interest  ................................ ................................ .............................  16 
8.3.9  Reporting of Pregnancy  ................................ ................................ ................................  16 
8.4 Unanticipated Problems  ................................ ................................ ................................ ....................  16 
8.4.1  Definition of Unanticipated Problems  ................................ ................................ ..........  16 
8.4.2  Unanticipated Problems Reporting  ................................ ................................ ..............  16 
8.4.3  Reporting Unanticipated Problems to Participants  ................................ ...................  17 
9 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ..........  17 
9.1 Statistical Hypotheses  ................................ ................................ ................................ .......................  17 
9.2 Sample Size Determination  ................................ ................................ ................................ ..............  17 
9.3 Populations for Analyses  ................................ ................................ ................................ ..................  17 
9.4 Statistical Analyses Plan ................................ ................................ ................................ ...................  18 
9.4.1  General Approach  ................................ ................................ ................................ ..........  18 
9.4.2  Analysis of the Primary Endpoint(s)  ................................ ................................ ............  18 
9.4.3  Analysis of the Secondary Endpoint(s)  ................................ ................................ .......  18 
9.4.4  Safety Analyses  ................................ ................................ ................................ ..............  18 
9.4.5  Baseline Descriptive Statistics  ................................ ................................ .....................  18 
9.4.6  Planned Interim Analyses  ................................ ................................ .............................  18 
9.4.7  Sub-Group Analyses  ................................ ................................ ................................ ..... 19 
9.4.8  Tabulation of Individual Participant Data  ................................ ................................ .... 19 
9.4.9  Exploratory Analyses  ................................ ................................ ................................ ..... 19 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ..............................  19 
10.1  Regulatory, Ethical, and Study Oversight Considerations  ................................ ...........................  19 
10.1.1  Informed Consent Process  ................................ ................................ ...........................  19 
10.1.2  Study Discontinuation and Closure  ................................ ................................ .............  19 
10.1.3  Confidentiality and Privacy  ................................ ................................ ...........................  20 
10.1.4  Future Use of Stored Specimens and Data  ................................ ...............................  21 
10.1.5  Key Roles and Study Governance  ................................ ................................ ..............  21 
10.1.6  Safety Oversight  ................................ ................................ ................................ .............  21 
10.1.7  Clinical Monitoring  ................................ ................................ ................................ ..........  21 
10.1.8  Quality Assurance and Quality Control  ................................ ................................ .......  22 
10.1.9  Data Handling and Record Keeping  ................................ ................................ ............  22 
10.1.10  Protocol Deviations  ................................ ................................ ................................ ........  23 
10.1.11  Publication and Data Sharing Policy  ................................ ................................ ...........  24 
10.1.12  Conflict of Interest Policy  ................................ ................................ ..............................  24 
10.2  Additional Considerations  ................................ ................................ ................................ .................  24 
10.3  Abbreviations and Special Terms  ................................ ................................ ................................ ... 24 
10.4  Protocol Amendment History  ................................ ................................ ................................ ...........  26 
11 REFERENCES  ................................ ................................ ................................ ................................ .............  27 
12 ATTACHMENT  ................................ ................................ ................................ ................................ .............  28 
 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 1 STATEMENT OF COMPLIANCE  
 
The trial will be carried out in accordance with International Council on Harmonisation  Good Clinical 
Practice ( ICH GCP) and the following :  
 
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 
46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312 , and/or 21 CFR Part 8 12).  
 
National Institutes of Health ( NIH)-funded investigators and clinical trial site staff who are 
responsible  for the conduct, management, or  oversight of NIH -funded clinical trials  have 
completed Human Subjects Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the IRB for review and approval. Approval of both the protocol and the consent 
form (s) must be obtained before any participant is consented . Any amendment to the protocol 
will require review and approval by the IRB before the changes are implemented to the study. All 
changes to the consent form (s) will be IRB approved; a determination will be made regarding 
whether  a new consent needs to be obtained from participants who provided consent, using a 
previously  approved consent form.  
  
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 2 INVESTIGATOR’S SIGNATURE  
The signature below constitutes the approval of this protocol and provides the necessary assurances 
that this study will be conducted according to all stipulations of the protocol, including all statements 
regarding confidentiality, and according to local legal and regulatory requirements and applicable US 
federal regulations and ICH guidelines , as described in the Statement of Compliance  above . 
 
Principal Investigator or Clinical Site Investigator:  
Signed:  
 Date:  03-18-2024  
 Name:  Yi-Yuan Tang   
 Title:  Professor   
 
Investigator Contact Information  
Affiliation:  Arizona State University  
Address:  425 N 5th St, Phoenix, AZ 85004  
Telephone : 4807903577  
Email:  yiyuan@asu.edu  
 
 
 
 
  

Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 3 1 PROTOCOL SUMMARY  
1.1 SYNOPSIS   
 
Title:  Brain Mechanisms of Reducing Polysubstance Use Following a Novel 
Body -mind Intervention  
Grant Number:  R61AT010138  
Study Description : The R61 phase of the study aims to understand the mechanisms and 
training effects of evidence -based body -mind training on self-control in 
polysubstance use. Specifically, it aims to understand brain mechanisms 
of improved self -control following an evidence -based preventive 
intervention - integrative body -mind training (IBMT).  
Objectives:  
 Primary Objective:  This study  aims to examine brain mechanisms of 
improved self-control following IBMT . 
Endpoint s: Primary Endpoint:  Brain  outcome  
Study Population:  70 adults (both sexes) who are at least 18 years old  with polysubstance 
use in the Lubbock , TX. 
Phase  or Stage:  N/A  
Description of 
Sites /Facilities  Enrolling 
Participants : The participating site/facility is Texas Tech  University, where 
enrollment of participants happens. There is no foreign site.   
Description of Study  
Intervention /Experimental 
Manipulation : Experimental manipulation is evidence -based preventive intervention - 
integrative body -mind training (IBMT)  and will be offered as a group 
for 10 sessions across 4 weeks . 
Study Duration:  12 months  
Participa nt Duration:  3 months  
1.2 SCHEMA   
 
  
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 4 Figure 1. Flowchart of screening , inclusion , and assessment  process  
 
Screening  
 
 
 
Visit 1  
Day 1  
 
 
 
 
 
 
 
 
 
 
 
 
Visit s 2-11 
Day 3 ± 1 to  
Day 30 ± 1 
 
Visit 12 
Day 31 ± 2 
 
Visit 13 
Day 90 ± 2  Total N: 70 
screen potential participants  by inclusion and exclusion  criteria; schedule Visit 1.  
Conduct informed consent process. Perform baseline assessments.  
 
Details refer to Section 1.3, Schedule of Activities  
 
Arm 2  
N = 35  Arm 1  
N = 35  
Administer study intervention Session 1 to Session 10  Randomize  
Post -Intervention assessments   
Follow -up assessments  
Details refer to  Section 1.3, 
Schedule of Activities  
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 5 1.3 SCHEDULE OF ACTIVITIES  
 
  
 
Pre-screening   
 
Visit 1  
Day 1  
Visit 2 to Visit 
11 
Day 3 ±1 to Day 
30±1 
Visit 12  
 Day 31 ±2 
Visit 13  
Day 90 ±2 
Review Eligibility X     
Informed Consent   X    
Demographics   X    
Outcome Evaluation       
Brain Assessment ( MRI 
scan )  X  X X 
Cognitive  Assessment 
(Self-control tasks )  X  X X 
Randomization   X    
Control & Experimental Interventions   X X   
Adverse Events Reporting   X X X X 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 6 2  INTRODUCTION  
2.1 STUDY R ATIONALE   
Polysubstance use ties with numerous consequences for adults, including poor performance, impaired 
driving, injuries,  risky behaviors (e.g., unsafe sex), increased risk for substance use disorders (SUDs),  and 
heightened risk for morbidity and mortality. Treatment outcomes, however, are far  from optimal since 
treatments often fail to capitalize on important target domains  linked to addiction outcomes.  We propose 
to address this urgent and critical public health issue by examining the  effectiveness of a brief evidence -
based mindfulness intervention  – Integrative Body -Mind Training (IBMT)  in adults with polysubstance use  
through ra ndomized  clinical trials (RCTs). We will examine if the intervention can improve  brain function 
and structure in self -control related regions and networks , thereby reducing polysubstance use . 
Outcomes from this study will inform  prevention and  treatment option to promote health and well -being 
for individuals with polysubstance use . 
2.2 BACKGROUND   
Tobacco use is the leading cause  of cancer and the leading preventable cause of death. Alcohol use is 
responsible for ~88,000 deaths each year  in the U.S. and is another primary preventable cause of cancer. 
The combined use of cigarettes and alcohol is  associated with an increased risk of mortality and 
morbidity.1 Previous  research shows that one target domain (mechanism) for polysubstance  use involves 
deficits in self -control  networks including the prefrontal cortex (PFC), the anterior cingulate cortex (ACC), 
and the ACC -Striatum  circuit.31-33 Deficits in self -control have been linked to SUDs, and can b e ameliorated 
through interventions.11,29-36 Mind Body Interventions  such as mindfulness meditation (MM) have shown 
to decrease substance use and have the potential to minimize negative outcomes resulting from  deficits 
in self -control.2,11,31 -36 Although research suggest MM is efficacious at reducing problematic use,  some 
studies are replete with limitations including the lack of: adequate control conditions, effective  
mindfulness programs, and assessments for biomarkers of change.37-39 As a result, the support for MM 
has been less robust in some work,40 thereby warranting more rigorous randomized controlled trials using  
appropriate MM program and active control, as well as standardized and theoretically driven 
assessments.  Self-control/EF and attention deficits can be improved through brief intervention.  Our 
preliminary RCTs in healthy adults provide support for our clinical trial by showing  improvement in self -
control/EF, attention, cognitive functioning, emotion, stress reduction, and quality of life following brief 
IBMT intervention, 2-30 suggesting  its potential effectiveness in adults with  polysubstance use . 
2.3 RISK/BENEFIT ASSESSMENT   
2.3.1  KNOWN  POTENTIAL RISKS  
The study includes behavioral, cognitive, and brain assessments, as well as mindfulness -based 
intervention.  
Behavioral and Cognitive Assessments  
• Immediate risks:  Potential boredom from completing the questionnaires and interviews.  
• Long -term risks:  Data including self -report, questionnaires and interview  involve risk of  breaches 
in confidentiality . 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 7 • Alternative procedures: There are no other available alternative procedures to assess behavior and 
cognition, since to assess the behavior and cognition, we have to use the actual assessments. To 
minimize immediate risks, breaks in between questionnaires and interviews are offered to reduce 
boredom. To minimize long -term risks, a ll information about the specific individuals will be 
maintained as confidential. Absolutely no names of subjects are used in published reports or in 
presentations in scientific mee tings. All data will be kept in locked files and digital media in the PI’s 
laboratory. Reference to individual subject data will be made with a number and letter code for 
each subject. Any risks to participants are minimal and are outweighed by the benefit s of 
increasing our scientific understanding of improving self -control and reducing polysubstance use . 
Brain  Assessments  
• Immediate risks: Potential boredom from completing the MRI scan, t he possibility of becoming 
uncomfortable in the enclosed space of the scanner.  
• Long -term risks:  MRI d ata involve s risk of breaches in confidentiality . 
• Alternative procedures: There are no other available alternative procedures to brain, since to 
assess the brain, we have to use the actual MRI assessments.  
 
Mindfulness -based Intervention  
• Immediate risks: Potential boredom from completing the intervention .  
• Long -term risks:  No known risk  based on our previous studies1. 
• Alternative procedures: There are no other available alternative procedures, since the goal is to 
test the effects of the mindfulness -based intervention. To minimize immediate risks, breaks during 
the session are offered to reduce boredom.  
2.3.2  KNOWN POTENTIAL BENEFITS  
Immediate potential benefits  
The immediate potential benefits from participant in this study includ e that participants generally 
find the experimental paradigms enjoyable (i.e. meditation and relaxation state) during the 
intervention sessions1.  
Long -term potential benefits  
The long -term potential benefits include that participants  have the opportunity to  learn more 
about approaches and methods of improving self-control  during the intervention and may be able 
to apply the learned knowledge in their everyday life  and reduce polysubstance  use.  
2.3.3  ASSESSMENT OF POTENTIAL RISKS AND BENEFITS  
Because this is a study that examines the effects of an intervention on behavior, cognition, and behavior, 
it is inevitable to expose participants to risk of boredom during their assessments and interventions, as 
these assessments and intervention are nece ssary for us to evaluate the effects of the intervention.  
 
To minimize immediate risks of potential boredom from completing the behavioral and cognitive 
assessments, brain assessments, and mindfulness -based intervention, breaks during the assessments and 
interventions are offered to reduce boredom and give participants time to rest. To minimize long -term 
risks, all information about the specific individuals will be maintained as confidential. Absolutely no names 
of subjects are used in published reports or in presentations in scientific meetings. All data will be kept in 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 8 locked files and digital media in the PI’s laboratory. Reference to individual subject data will be made with 
a number and letter code for each subject.  
Based on the risks of boredom and breach in confidentiality, as well as our approaches to minimize these 
risks, we conclude that an y risks  to participants are minimal and are outweighed by the benefits of 
increasing our scientific understanding of improving self-control in  adults  with polysubstance use , as well 
as the benefits of potentially having the participants learning ways to improve  self-control and potentially 
reduce polysubstance use  in their everyday life.  
3 OBJECTIVES AND ENDPOINTS   
 
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  
Primary    
This study aims to investigate 
the modulation effects of a 
novel body -mind intervention 
on brain  outcomes.  
 
 
 
 Baseline and post -
intervention 
assessments of 
brain  outcomes  
(functional activity 
in anterior 
cingulate 
cortex/medial 
prefrontal cortex ). The novel body -mind 
intervention should lead to 
improvement in brain 
outcomes at post -intervention  
compared to baseline.  
Secondary    
N/A N/A  
 
 N/A   
Tertiary/Exploratory    
N/A N/A  
 
 N/A   
 
4 STUDY DESIGN  
4.1 OVERALL  DESIGN  
The study is a randomized control trial (RCT) involving two groups – IBMT (Arm 1: experimental 
manipulation) and RT (Arm 2: control group) group. Participants in each group  will be assessed at 
baseline  and post -intervention  using behavioral  and brain assessments as described in Section 1.3 . 
Automatic  randomization will be conducted by study staff and used to assign participants to  each 
arm/group condition  using an algorithm before the baseline assessment . This randomization 
procedure ensures balance between  groups on gender while also balancing total treatment numbers .  
4.2 SCIENTIFIC R ATIONALE FOR STUDY DESIGN  
To evaluate the effects of our experimental manipulation, we need an active control group for this RCT 
study design. The RT has been used as a control condition in many previous published studies and is an 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 9 accepted control intervention. Thus, we use it as a control condition in our study design. There are no  
known or potential problems associated with the control group.3-5,8-12 
4.3 JUSTIFICATION FOR INTERVENTION  
The chosen 10 -sessions of experimental manipulation - IBMT has been shown to improve behavior, 
cognition, and brain in previous RCTs in healthy adults. Thus, we choose to use the same setup and design, 
and expect the same length and frequency of the interv ention would be  appropriate for adults with 
polysubstance use .  
4.4 END-OF-STUDY DEFINITION  
 
A participant is considered to have completed the study if he or she has completed the baseline 
assessment, 10 intervention sessions, and post -intervention assessment .  
5 STUDY POPULATION  
5.1 INCLUSION CRITERIA  
In order to be eligible to participate in this study, an individual must meet all of the following criteria:  
1. At least 18 years old  
2. Free of any psychiatric diagnoses or medication (besides a SUD to alcohol, tobacco, or cannabis  
3. In the past month, at least 4 episode s of heavy episodic drinking; at least 3 occasion of cannabis 
use; and daily cigarette use for at least the past month  
4. Normal or corrected -to-normal vision  
5. Written informed consent  
6. No previous meditation or neurofeedback  experiences  
5.2 EXCLUSION CRITERIA  
An individual who meets any of the following criteria will be excluded from participation in this study:  
1. Any psychiatric diagnoses other than an SUD  
2. Medical disorder(s) that may affect the central nervous system; medications that affect the 
central and autonomic nervous system; or a positive pregnancy test result (females)  
3. Excluding cannabis, evidence of recent (past month) illicit drug use.  
5.3 LIFESTYLE CONSIDERATIONS  
N/A 
 
5.4 SCREEN FAILURES  
Screen failures are defined as participants who consent to participate in this study  but are not 
subsequently assigned to the study intervention or entered in the study. Individuals  who do not meet the 
criteria for participation in this trial (screen failure) because of meeting one or more exclusion criteria that 
are likely to change over time may be rescreened. Examples include the successful removal of metal 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 10 devices that previously made them ineligible for a n MRI scan. Rescreened participants will be assigned 
the same participant number as for the initial screening.  
5.5 STRATEGIES FOR RECRUITMENT AND RETENTION  
We anticipate to enroll 70 participants (males and females) who are at least 18  years old across different 
race and ethnicity based on local demographic characteristics . Subjects will be recruited through print and 
media ads within local community . This will include radio and online ads and recruitment through social 
media. Flyers will be distributed throughout the local community. Based on our and other’s previous  
experiences in longitudinal studies, about 5 -10% of participants will dropout over the study  period  
due to illness or relocation. We plan a dropout rate of 20% for this brief intervention  given the population  
is polysubstance users . We propose to recruit 70 adults of which 56 (80%) will complete the study.   
Compensation and Retention. Participants will be financially compensated with $ 300 in total for 
completing the study protocol (approximately for 15 hours of time); participants who only partially 
complete the protocol will be compensated  based on prorated hours . To maximize participant retention 
we will maintain contact with participants over time via frequent assessment intervals (e.g., requiring a 
functioning phone number and email address to contact participants by phone or email as needed, and 
obtaining the name, address, and phone number of at least 2 friends or classmates who can provide 
contact information for the participants, should we be unable to contact th em during the study; emails 
and reminder phone calls prior to all study visits; offer flexible scheduling options for assessment (including 
weekends); provide fair compensation to participants;  and maintain positive relations with participants. 
These procedures were used to maintain adequate participant retention in our prior NIH studies.  
6 STUDY INTERVENTION(S) OR EXPERIMENTAL MANIPULATION(S)  
6.1 STUDY INTERVENTION (S) OR EXPERIMENTAL MANIPULATION(S)  ADMINISTRATION  
6.1.1  STUDY INTERVENTION  OR EXPERIMENTAL MANIPULATION  DESCRIPTION  
Experimental Manipulation – IBMT (Arm 1):  IBMT emphasizes the cooperation  between body and mind in 
facilitating and achieving a meditative state ecologically.2-12 Each IBMT session  is facilitated by an 
experienced coach who has demonstrated the ability to attain the appropriate  state of body and mind, 
and to lead the group to achieve a similar state. The coach creates a harmonious and  relaxed atmosphere, 
observes facial and body cues to identify those who are struggling with the method, and  gives proper 
feedback for effective practice. IBMT coach helps subjects attain desired state by first providing a  brief 
period to induce a cognitive or emotional state that will facilitate the training. Then, coach helps subjects  
find an approp riate and balanced body posture and follow instructions to achieve deeper levels of relaxed 
body  (physiology of relaxation) and experience a restful feeling and mental quiet (psychology of 
relaxation) mindfully.  When the mind wanders, the coach helps subjects accept and be open to 
experiences without judgment, and  further guides subjects to use a favorite mental image as a tool to 
return to the present moment gently. At last,  the coach facilitates a brief group discussion to ensure 
subjects having positive experiences consistent with the  intent of IBMT. The method stresses no effort to 
control thoughts, but instead emphasizes a state of restful  alertness that allows a high degree of 
awareness of the body, mind, and environment. 2-12 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 11 Control Intervention  – RT (Arm 2): For RT, each session includes pre -, post - and practice sessions, similar 
to IBMT procedure  and is facilitated by a trained coach . However, RT involves relaxing different muscle 
groups over the face, head, shoulders, arms, legs, chest, back,  and so on, guided by the experienced and 
certified coach. With eyes closed and in a sequential pattern, one  concentrates on the sensation of 
relaxation, such as feelings of warmth and heaviness. Therefore, RT includes  relaxation and imagery (no  
mindfulness component) and could serve as an ideal active control. Along with  other groups, we have been 
using RT as active control in our RCTs. 2-12 The progressive training helps achieve  physical and mental 
relaxation and calmness.  
6.1.2  ADMINISTRATION  AND/OR DOSING  
Both arms of interventions will be administered face -to-face as a group by trained interventionists. Both 
interventions will have 10 group sessions, and the completion of all 10 sessions is considered to be having 
a “full -dose” intervention. Participants i n the same arm /group  will interact with a shared interventionist.  
6.2 FIDELITY  
6.2.1  INTERVENTIONIST TRAINING  AND TRACKING  
Explicit coach selection criteria and on -going monitoring and supervision  of treatment delivery and fidelity 
will ensure that the interventions are of the highest quality, follow the protocols  precisely, and prevent 
coach drift and contamination. For IBMT and RT, the coach must have a minimum of a  master’s degree in 
psychology, social work, or a related field and experience running group therapy. The  coach will need to 
meet additional criteria: have completed the trainer course, had a daily practice of  mindfulness, and 
attended a silent meditation retreat. To monitor coach’s adherence and competence, all  sessions will be 
recorded and a random sample of 10% will be rated by the investigators using the modified  Adherence 
Scale to ensure the interventionist has adequate competence and adherence to the protocols, and to 
prevent drift.  
6.3 MEASURES TO MINIMIZE BIAS : RANDOMIZATION  AND BLINDING  
To minimize potential biases, participants are randomized based on automatic  covariate conducted by Co -
I using an adaptive  algorithm . Participants are blinded to the intervention. Specifically, they were told that 
they will be engaged in body -mind intervention, without knowing whether or not the intervention they 
received is the experimental manipulation or control intervention. See methods of analysis in Section 9, 
Statistical Considerations  for details on randomization . Additionally, research staff who assesses 
participants are also blinded of the participants’ intervention condition. Randomization code is maintained 
by the Co -I. A planned breaking of randomization code and blinding would occur  for any participants  who 
reported serious adverse eve nts. The PI and Co -I will identify which group the participant is in, without the 
need for research staff to be involved in knowing the participant’s intervention group.  
6.4 STUDY INTERVENTION /EXPERIMENTAL MANIPULATION  ADHERENCE  
Participants’ adherence  with study procedures will be tracked  by taking their  attendance at intervention 
visits . Moreover, i n each session, we use  participant  self-report and coach observation to calculate study 
intervention adherence  by the participant based on their engagement and quality of practice .  
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 12 6.5 CONCOMITANT THERAPY  
N/A  
6.5.1  RESCUE THERAPY  
N/A  
 
7 STUDY INTERVENTION /EXPERIMENTAL MANIPULATION  DISCONTINUATION  AND 
PARTICIPANT  DISCONTINUATION /WITHDRAWAL  
7.1 DISCONTINUATION  OF STUDY INTERVENTION /EXPERIMENTAL MANIPULATION  
If a clinically sig nificant finding is identified (including, but not limited to changes from baseline) after 
enrollment, the investigator or quali fied designee will determine if any change in participant management 
is needed. Any new clinically relevant finding will be reported as an adverse event (AE) . 
 
The data to be collected at the time of study intervention discontinuation will include the following:  
• The reason(s) for discontinuing the participant from the intervention, and methods for 
determining the need to discontinue  
• If the participant is due to complete assessments within 1 weeks of being discontinued from the 
study intervention, those assessments will be administered at the time of discontinuation; if the next 
scheduled assessments are more than 1 week from the discontinuation date, the next scheduled 
assessment  will not be administered . Thereafter, the participant will be  not included in all future 
scheduled assessments, as they did not participat e in the intervention.  
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL FROM THE STUDY  
Participant s are free to withdraw from participation in the study at any time upon request.  
An investigator may discontinue  a participa nt from  the study for the following reasons : 
 
• Significant study intervention non-compliance , unless varying compliance is an aspect of the study 
objectives   
• Lost-to-follow up; unable to contact subject  (see Section 7.3, Lost to Follow -Up) 
• Any event or medical condition or situation occurs such that continued collection of follow -up  
study data would not be in the best interest of the participant  or might require an additional 
treatment that would confound the interpretation of the study  
• The participant  meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation  
 
The reason for participant discontinuation  or withdrawal from the study will be recorded . Subjects who 
sign the informed consent form and are randomized but do not receive the study intervention may be 
replaced. Subjects who sign the informed consent form, and are randomized and receive the study 
intervention , and subsequently withdraw, or are discontinued from the study, will not be  replaced.  
7.3 LOST TO FOLLOW -UP 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 13 A participant will be considered lost to follow -up if he or she fails to return for 1 scheduled visit  and study 
staff  are unable to contact the participant after at least 3 attempts .  
 
The following actions must be taken if a participant fails to return for a required study visit:  
 
• The site will attempt to contact the participant , reschedule the missed visit within 1 week , counsel 
the participant on the importance of maintaining the assigned visit schedule and ascertain if the 
participant wishes to and/or should continue in the study  
• Before a participant is deemed lost to follow -up, the investigator or designee will make every 
effort to regain contact with the participant (where possible, 3 telephone calls and, if necessary, 
a certified letter to the participant’s last known mailing address or local equivalent methods) .  
• Should the participant  continue to be unreachable, he or she will be considered to have 
withdrawn from the study with a primary rea son o f lost to follow -up. 
8 STUDY ASSESSMENTS AND PROCEDURES  
8.1 ENDPOINT AND OTHER NON -SAFETY ASSESSMENTS  
The study involves assessing participants at baseline, post -intervention, and one -month follow -up. The 
participant will be screened for eligibility after consenting. They will fill out demographic questionnaires 
and MRI screening form to determine their eligibility. Next, they will undergo behavioral  and brain 
assessments by trained research staff and/or MRI technician. All non -brain assessments will be conducted 
at PI’s lab for all participants to decrease variability. All brain assessments will be conducted at Barrow 
Neurological Institute for all pa rticipant s to decrease variability.    
 
Below is  a list and description of  the assessments : 
• Imaging assessments   
MRI Scan – provides images of brain structure and function  
• Administration of questionnaires , interviews  
Behavioral assessments – demographic  questionnaire, subjective reports of polysubstance use  
8.2 SAFETY ASSESSMENTS  
N/A 
 
8.3 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
8.3.1  DEFINITION OF ADVERSE EVENTS  
 
This protocol uses the definition of a dverse event from 21 CFR 312.32 (a) : any untoward medical 
occurren ce associated with the use of an intervention in humans, whether or not considered intervention -
related . 
 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 14 8.3.2  DEFINITION OF SERIOUS ADVERSE EVENTS  
 
This protocol uses the definition of serious adverse event includes: (a) Death; (b)  Hospitalization (initial or 
prolonged) ; (c) Life -threatening condition; (d) Disability or Permanent Damage ; (e) Other Serious 
(Important Medical Events) . 
 
 
8.3.3  CLASSIFICATION OF AN ADVERSE E VENT  
8.3.3.1  SEVERITY OF EVENT  
 
For adverse events ( AEs) not included in the protocol defined grading system, the following guidelines will 
be used to describe severi ty.  
 
• Mild  – Events require minimal or no treatment and do not interfere with the participant ’s daily 
activities.   
• Moderate  – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
• Severe  – Events interrupt a participant ’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life -threatening or 
incapacitating.   Of note, the term  “severe” does not necessarily equate to “serious”.  
 
8.3.3.2  RELATIONSHIP TO STUDY INTERVENTION /EXPERIMENTAL MANIPULATION  
 
All adverse events ( AEs) will have their relationship to study procedures, including the intervention , 
assessed  by an appropriately -trained clinician  based on temporal relationship and his/her clinical 
judgment. The degree of certainty about causality will be graded using the categories below.  
 
• Related  – The AE is known to occur with the study procedures , there is a reasonable possibility 
that the study procedures  caused the AE, or there is a temporal relationship between the study 
procedures  and the event. Reasonable possibility means that there is evidence to suggest a causal 
relationship between the study procedures  and the AE. 
• Not Related  – There is not a reasonable possibility that the study procedures  caused the event, 
there is no temporal relationship between the study procedures  and event onset , or an alternate 
etiology has been established.  
 
8.3.3.3  EXPECTEDNESS  
 
A clinician with appropriate expertise in medical care  will be responsible for determining whether an 
adverse event ( AE) is expected or unexpected. An AE will be considered unexpected if the nature, severity, 
or frequency of the event is not consistent with the risk information previously described for the study 
procedures . 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 15 8.3.4  TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
 
The occurrence of an adverse event ( AE) or serious adverse event ( SAE) may come to the attention of 
study personnel during study visits and interviews of a study participant  presenting for medical care, or 
upon review by a study monitor.  
 
All AEs , not otherwise precluded per the protocol,  will be captured on the appropriate  case report form  
(CRF). Information to be collected includes event description, time of onset, clinician’s assessment of 
severit y, relationship to study procedures  (assessed only by those with the training and authority to make 
a diagnosis), and time of resolution/stabilization of the event. All AEs occurring while on study will be 
documented appropriately regardless of relationship. All AEs will be followed to adequate resolution.  
 
Any medical or psychiatric condition that is present at the time that the participant  is screened will be 
considered as baseline and not reported as an AE. However, if the study participant’s condition  
deteriorates at any time during the study, it will be recorded as an AE.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity  to be performed. Documentation of onset and duration of each episode  will be 
maintained for AEs characterized as intermittent . 
 
PI will record events with start dates occurring any time after informed consent is obtained until 7 (for 
non-serious AEs) or 30 days (for SAEs) after the last day of study participation.  At each study visit, the 
investigator will inquire about the occurrenc e of AE/SAEs since the last visit.  Events will be followed for 
outcome information until resolution or stabilization.  
8.3.5  ADVERSE EVENT REPORTING  
In consultation with the PI, a trained member of the study team will be  responsible for conducting an 
evaluation of an adverse event  and shall report the results of such evaluation to the NIH and the reviewing 
Institutional Review Board ( IRB) as soon as possible, but in no event later than within 24 hours after the 
investigator first learns of the event.  
 
8.3.6  SERIOUS ADVERSE EVENT REPORTING  
 
In consultation with the PI, a trained member of the study team will be  responsible for conducting an 
evaluation of a serious adverse event  and shall report the results of such evaluation to the NIH and the 
reviewing Institutional Review Board ( IRB) as soon as possible, but in no event later than within 24 hours  
after the investigator first learns of the event.  
 
8.3.7  REPORTING E VENT S TO PARTICIPANTS  
 
The PI will be responsible for reporting AEs or SAEs related to the study to participants as soon as possible, 
but in no event later than within 24 hours  after the investigator first learns of the event.  
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 16 For incidental findings from MRI brain scan, the MRI facility will inform the PI  if there is incidental finding  
and the PI will report the finding to participants as soon as possible, but in no event later than within 24 
hours  after the investigator first learns of the event.  
 
8.3.8  EVENTS OF SPECIAL INTEREST  
N/A 
8.3.9  REPORTING OF PREGNANCY  
N/A  
8.4 UNANTICIPATED PROBLEMS  
 
8.4.1  DEFINITION OF U NANTICIPATED PROBLEMS  
This protocol uses the definition of Unanticipated Problems as defined by t he Office for Human Research 
Protections ( OHRP ).  OHRP  considers unanticipated problems involving risks to  participant s or others to 
include, in general, any incident, experience, or outcome that meets all of the following criteria:  
 
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are 
described in the protocol -related documents, such as the Institutional Review Board ( IRB)-
approved research protocol and informed consent document; and (b) the characteristics of the 
participant  population being studied;  
• Related or possibly related to participation in the research (“possibly related” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by the 
procedures involved in the research); and  
• Suggests that the research places participant s or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
 
8.4.2   UNANTICIPATED PROBLEM S REPORTING  
The investigator  will report unanticipated problems ( UPs) to the reviewing Institutional Review Board 
(IRB) and t o the Data Coordinating C enter ( DCC)/lead principal investigator ( PI). The UP report will include 
the following information:  
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project 
number  
• A detailed description of the event, i ncident, experience, or outcome   
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP 
• A description of any changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the UP 
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:   
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 17  
• UPs that are serious adverse events ( SAEs) will be reported to the IRB and to the DCC/study 
sponsor /funding agency  within 10 business days  of the investigator becoming aware of the event .  
• Any other UP will be reported to the IRB and to the DCC/study sponsor /funding agency  within 10 
business days  of the investigato r becoming aware of the problem   
• All UPs should be reported to appropriate institutional officials (as required by an institution’s 
written reporting procedures), the supporting agency head (or designee), and the Office for 
Human Research Protections ( OHRP ) within 10 business days  of the  IRB’s receipt of the report of 
the problem from the investigator . 
 
8.4.3  REPORTING UNANTICIPATED PROBLEMS  TO PARTICIPANTS  
The PI will be responsible for reporting UPs related to the study to participants as soon as possible, but in 
no event later than 10 working days after the investigator first learns of the UP.  
 
9 STATISTICAL CONSIDERATIONS   
9.1 STATISTICAL HYPOTHESES  
 
• Primary Endpoint(s):   
We hypothesize that, compared to participants  who receive a RT control intervention , participants  
who receive IBMT  for improving brain outcomes  will have improved anterior cingulate cortex/medial 
prefrontal cortex functional activity  after completing the intervention at post -assessment . 
Alternatively, our null hypothesis is that there will be no difference in the effects of IBMT  for improving 
brain outcomes and those of RT  at post -assessment . 
9.2 SAMPLE SIZE  DETERMINATION  
Our RCT design is focused on determining if within -person brain changes significantly differ across the 
intervention groups. All participants in this study will be  those who use polysubstance . In prior work 
involving  smokers (N = 27), we detected significant fMRI signal changes in the ACC/mPFC (Cohen’s d= .90) 
after 2 -wk of IBMT than before IBMT  11,24. Compensating for the expected variability of findings in 
ACC/mPFC activity in polysubstance  use, we thus expect a conservative, medium  to large  (Cohen’s d = .80) 
effect (i.e., we expect the effect size between the intervention and control conditions to  be 0.80  at post -
intervention ) based on ours and other studies.8-11,41,42 However, we may expect polysubstance users to be 
somewhat more variable. Given the power consid erations, we increased our sample size to 35 per  group, 
which will give us 90% power to detect fMRI signal changes evoked by IBMT.  The target sample size for 
the proposed study in the R61 phase (n = 70; 35/condition) is designed to  provide sufficient evidence to 
detect significant brain changes in ATC users following interventions. Given we  anticipate up to 20% 
attrition across the R61 phase of the study, power analysis suggests adequate power .  
9.3 POPULATIONS FOR ANALYSES  
The analysis population will be M odified Intention -to-Treat Analysis Population. Specifically, these 
participants are those who completed the full -dose of the intervention (10 sessions) and have 
completed data for the primary endpoint.   
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 18 9.4 STATISTICAL ANALYSES  PLAN  
9.4.1  GENERAL APPROACH  
Behavioral and brain data analysis will undergo separate analyzing streams to test intervention  effects 
and underlying mechanisms at baseline and post -intervention . Given the scope of this 2-year  R61 
project, the  logical first step at this early stage of research is to examine the potential intervention 
effects and mechanisms, then move to the full scale RCTs for R33 phase . To address our study Aims, 
repeated -measures ANOVA will be used. By utilizing all assessment points, this approach allows for 
well-powered  tests to detect significant differences in changes across the experimental conditions, 
even when assuming  smaller magnitude effect sizes . Effect size measures (from the repeated -
measures ANOVA,  Cohen’s d highl ighting mean differences between treatment and control groups 
across assessments) will also  be calculated to describe the intervention’s effect on study outcomes.  
9.4.2  ANALYSIS OF THE PRIMARY ENDPOINT(S)  
The primary endpoints are brain  assessments  and are all repeated measures assessed at baseline  and post -
intervention . For brain assessment of brain assessment of functional activity , whole -brain analyses  of fMRI 
timeseries during resting state will be calculated and for all endpoints based on standardized processing 
pipelines of fMRI data using REST software ( www.restfmri.net ). After these d ata preprocessing  and 
calculation, numerical values will be generated  for each brain voxel . Next, the effects of intervention (IBMT 
vs. RT) on primary endpoints will be examined using repeated -measures ANOVA with time x group 
interaction effect. Threshold -free cluster enhancement  approach will be used to identify clusters showing 
significant effects.  Variance and covariance across repeated measures will be calculated as part of the 
ANOVA. Age and sex will be included as covariates to control for potential confounding effects of age and 
sex on brain outcomes . Results will be presented as F values for the interaction effect, along with p values 
to indicate statistical significance. Normality and homogeneity of variance assumptions will be checked 
using SPSS built -in tools for ANOVA. Multiple comparison corrections will be conducted using  FDR 
correction . Missing data will be handled with case -wise deletion . 
9.4.3  ANALYSIS OF THE SECONDARY ENDPOINT(S)  
N/A 
9.4.4  SAFETY ANALYSES  
N/A 
 
9.4.5  BASELINE DESCRIPTIVE STATISTICS  
Intervention groups will be  compared on baseline characteristics  including demographics  and behavioral  
assessments of polysubstance use  using independent samples t -tests .  
 
9.4.6  PLANNED INTERIM ANALYSES  
 N/A 
 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 19 9.4.7  SUB -GROUP ANALYSES  
Sub-group analyses will not be conducted for primary and secondary outcomes for this pilot study, as the 
sample size of sub -groups (N<10) based on age, sex, race/ethnicity or other demographic characteristic(s ) 
will not be sufficient to conduct meaningful group analyses.  
 
9.4.8  TABULATION OF INDIVIDUAL PARTICIPANT DATA  
Individual participant  data will not be tabulated as the goal of the study is to examine group effects.  
 
9.4.9  EXPLORATORY ANALYSES  
N/A 
 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
10.1 REGULATORY, ETHICA L, AND STUDY OVERSIGHT CONSIDERATIONS  
10.1.1  INFORMED CONSENT PROCESS  
10.1.1.1  CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS   
 
Consent forms describing in detail the study intervention , study procedures, and risks will be  given to the 
participant  and written documentation of informed consent will be completed  prior to starting the study 
intervention.   The following consent materials are submitted with this protocol : 1. Consent Form.  
 
10.1.1.2  CONSENT PROCEDURES AND DOCUMENTATION  
Informed consent will be administered by a member of the study team to the participant. The team 
member will give the participant a brief overview of the consent form and summarize relevant information 
from each section of the consent form. Participants will then be given time to read the consent form on 
their own. The study population involves English speaking cognitively normal adults, so no special 
procedures are needed to obtaining the consent. Participants will be asked if they und erstand and 
comprehend the consent form and if they have any questions. These procedures serve as means for 
determining competency and assessing comprehension/understanding of the participants. Any questions 
the participants may have will be answered by th e team member.  Finally, participants are asked to indicate 
if they would like to enroll in the study or not by signing or not signing the consent form.  
10.1.2  STUDY DISCONTINUATION AND CLOSURE  
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause. Written notification, documenting the reason for study suspension or termination, will be provided 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 20 by the suspending or terminating party to study participants, funding agency, and regulatory authorities. 
If the study is prematurely terminated or suspended, the  Principal Investigator ( PI) will promptly inform 
study participants, the Instituti onal Review Board ( IRB), and sponsor /funding agency  and will provide the 
reason(s) for the termination or suspension. Study participants will be contacted, as applicable, and be 
informed of changes to study visit schedule.  
 
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Insufficient compliance of study staff to the protocol  (ie, significant protocol violations)  
• Pandemic, such as COVID -19 
 
The s tudy may resume once concerns about safety, protocol compliance, and data quality are addressed , 
and satisfy the funding agency, sponsor, IRB , Food and Drug Administration ( FDA), or other relevant 
regulatory or oversight bodies (OHRP, DSMB) . 
 
10.1.3  CONFIDENTIALITY  AND PRIVACY   
Participant  confidentiality  and privacy is strictly held in trust by the participating investigators, their staff, 
the safety and oversight monitor(s), and the sponsor(s)  and funding agency . This confidentiality is 
extended to the data being collected as part of this study. Data that could be used to identify a specific 
study participant will be held in strict confidence within the research team . No personally -identifiable 
information from the study  will be released to any unauthorized third party without prior written approval 
of the sponsor /funding agency .  
 
All research activities will be conducted in as private a setting as possible.  
 
The study monitor, other authorized representatives of the sponsor  or funding agency , representative s of 
the Institutional Review Board ( IRB), regulatory agencies , may inspect all documents and records required 
to be maintained by the investigator. The study site will permit access to such records.  
 
The study participant’s contact information will be securely stored at the study site  for internal use during 
the study. At the end of the study, all records will continue to be kept in a secure location for as long a 
period as dictated by the reviewing  IRB, Institutional policies, or sponsor /funding agency  requirements . 
 
Measures Taken to Ensure Confidentiality  of Data Shared per  the NIH Data Sharing Policies  
It is NIH policy that the results and accomplishments of the activities that it funds should be made available 
to the public (see  https://grants.nih.gov/policy/sharing.htm ). The PI will ensure all mechanisms used to 
share data will include proper plans and safeguards for the protection of privacy, confidentiality, and 
security for data dissemination and reuse  (e.g., all data will be thoroughly de -identified and will not be 
traceable to a specific study participant) . Plans for archiving and long -term preservation of the data will 
be implemented, as appropriate.  
 
Certificate of Confidentiality  
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 21 To further protect the privacy of study participants, the Secretary, Health and Human Services (HHS), has 
issued a Certificate of Confidentiality (CoC) to all researchers engaged in biomedical, behavioral, clinical 
or other human subjects research funded w holly or in part by the federal government.   Recipients of NIH  
funding for  human subjects research are required to protect identifiable research information from forced 
disclosure per the terms of the NIH Policy (see https://humansubjects.nih.gov/coc/index ). As set forth 
in 45 CFR Part 75.303(a)  and NIHGPS Chapter 8.3 , recipients conducting NIH -supported research covered 
by this Policy are required to establish and maintain effective internal controls (e.g., policies and 
procedures) that provide reasonable assurance that the award is managed in compliance with Federal 
statutes, regulations, and the terms and conditions of award. It is the NIH policy that investigators and 
others who have access to research records will not disclose identifying information except when the 
participant consents or in certain instances when  federal, state, or local law or regulation requires 
disclosure. NIH expects investigators to inform research participants of the protections and the limits to 
protections provided by a Certificate issued by this Policy.  
10.1.4  FUTURE USE OF STORED SPECIMENS  AND DATA   
Data collected for this study will be analyzed and stored at the  study site . After the study is completed, 
the de -identified, archived data will be transmitted to and stored at the study site’s  secured  data storage 
space. The use of the de -identified data by other researchers including those outside of the study  will be 
granted per reasonable requests.   
 
10.1.5  KEY ROLES  AND STUDY GOVERNANCE  
Principal Investigator  Independent Data Safety  
Monitor  
Yi-Yuan Tang, Ph.D., Professor  Elliot Stein , Ph.D. , Investigator  
Arizona State University   National Institute on Drug Abuse  
425 N 5th St, Phoenix, AZ 85004  251 Bayview Boulevard  Suite 
200, Baltimore, MD 21224  
4807903577  4437402650  
yiyuan@asu.edu  stein@mail.nih.gov  
 
10.1.6  SAFETY OVERSIGHT  
 
Safety oversight will be under the direction of a Data and Safety Monitoring Board  (DSMB)  composed of 
individuals with the appropriate expertise, including  clinical trials and intervention . Members of the DSMB 
will be independent from the study conduct and free of conflict of interest. The DSMB  will meet at least 
semiannually to assess safety and efficacy data from  each arm of the study. The DSMB  will operate under 
the rules of an approved charter that will be written and reviewed at the organizational meeting of the 
DSMB. At this time, each data element that the DSMB  needs to assess will be cl early defined. The DSMB 
will provide its input to NCCIH via annual report.  
 
10.1.7  CLINICAL MONITORING  
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 22 Clinical site monitoring will be  conducted to ensure that the rights and well -being of trial participants  
are protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct 
of the trial is in compliance with the currently approved protocol/amendment(s), with International 
Council on Harmonisation Good Clinical Practice (ICH GCP), and with applicable regulatory 
requirement(s). Monitoring activities will be  conducted by the study site itself, so please see Section  
10.1.8, Quality Assurance and Quality Control.  
 
10.1.8  QUALITY ASSURANCE AND QUALITY CONTROL  
 
The study  site will perform internal quality management of study conduct, data collection, docu mentation 
and completion. Quality control ( QC) procedures will be implemented as follows:  
 
Informed consent  --- Study staff will review both the documentation of the consenting process as well as 
a percentage of the completed consent documents.  This review will evaluate compliance with GCP, 
accuracy, and completeness.  Feedback will be provided to the study team to ensure proper consenting  
procedures are followed .  
 
Source documents  and the electronic data --- Data will be initially captured on source documents (see 
Section  10.1.9 , Data Handling and Record Keeping ) and will ultimately be entered into the study 
database .  To ensure accuracy site staff will compare a representative sample of source data against the 
database, targeting key data points in that review.  
 
Intervention Fidelity  — Consistent delivery of the study interventions will be monitored throughout the 
intervention phase of the study. Procedures for ensuring fidelity of intervention delivery are described in 
Section 6.2.1 , Interventionist Training and Tracking .  
 
Protocol Deviations  – The study team will review protocol deviations on an ongoing basis and will 
implement corrective actions when the quantity or nature of deviations are deemed to be at a level of 
concern.  
 
Should independent monitoring become necessary, t he PI will provide direct access to all trial related 
sites, source data/documents, and reports for the purpose of monitoring and auditing by the 
sponsor /funding agency , and inspection by local and regulatory author ities.  
 
10.1.9  DATA  HANDLING  AND  RECORD  KEEPING   
10.1.9.1  DATA COLLECTION AND  MANAGEMENT RESPONSIBILITIES  
 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 23 Data collection will be  the responsibility of study team  at the site under the supervision of the site 
investigator . The investigator will be  responsible for ensuring the accuracy, completeness, legibility, and 
timeliness of the data reported . 
 
All source documents will be completed in a neat, legible manner to ensure accurate interpretation of 
data.   
 
Hardc opies of the study visit worksheets  will be provided for use as source document  worksheets for 
recording data for each participant  consented/ enrolled in the study.  Data re cord ed in the electronic case 
report form ( eCRF ) derived from source documents will be consistent with the data recorded on the 
source documents .  
 
Clinical data (including adverse events ( AEs) and SAEs will be entered into RedCap  provided by the study 
site. The data system includes password protection and internal quality checks, such as automatic range 
checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered 
directly from the source documents . 
10.1.9.2  STUDY RECORDS RETENTION  
 
Study documents will be retained for a minimum of 2 years after the study completion date.  These 
documents should be retained for a longer period, however, if required by local regulations. No records 
will be destroyed without the written consent of the sponsor /funding agency , if applicable. It is the 
responsibility of the sponsor /funding agency  to inform the investigator when these documents no longer 
need to be retained.  
 
10.1.10  PROTOCOL DEVIATIONS   
 
This protocol defines a protocol deviation a s any noncompliance with the clinical trial protocol, 
International Council on Harmonisation Good Clinical Practice ( ICH GCP) , or Manual of Procedures ( MOP) 
requirements. The noncompliance may be either on the part of the participant , the investigator, or the 
study site staff. As a result of deviations, corrective actions will be developed by the site and implemented 
promptly.  
 
These practices are consistent with ICH GCP:  
• Section 4.5 Compliance with Protocol, subsections 4.5.1, 4.5.2, and 4.5.3  
• Section 5.1 Quality Assurance and Quality Control, subsection 5.1.1  
• Section 5.20 Noncompliance, subsections 5.20.1, and 5.20.2.  
 
It will be  the responsibility of the site investigator to use continuous vigilance to identify and report 
deviations within 10 working days of identification of the protocol deviation, or within 10 working days of 
the scheduled protocol -required activity. All deviations will be addressed in study source documents, 
reported to NCCIH  Program Official and NCCIH . Protocol deviations will be sent to the reviewing  
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 24 Institutional Review Board (IRB)  per their policies . The site investigator  will be  responsible for knowing 
and adhering to the  reviewing IRB requirements . 
 
10.1.11  PUBLICATION AND DATA SHARING POLICY   
 
This study will  be conducted in accordance with the following  publication and data sharing  policies and 
regulations:  
 
National Institutes of Health ( NIH) Public Access Policy , which ensures that the public has access to the 
published results of NIH funded research. It requires scientists to submit final peer -reviewed journal 
manuscripts that arise from NIH funds to the digital archive PubMed Central  upon acceptance for 
publication.  
 
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -Funded 
Clinical Trial Information and the Clinical Trials Registration and Results Information Submission r ule. As 
such,  this trial will be  registered at ClinicalTrials.gov , and results information  from this  trial will be 
submitted to ClinicalTrials.gov.  In addition, every attempt will be made to publish results in peer -reviewed 
journals.  Data from this study may be request ed from other researchers 10 years after the completion of 
the primary endpoint by contacting PI Yi -Yuan Tang .  Considerations for ensuring confidentiality of these 
shared data are described in Section 10.1.3 . 
10.1.12  CONFLICT OF  INTEREST  POLICY  
 
The independence of this study from any actual or perceived influence , such as  by the pharmaceutical 
industry , is critical . Therefore , any actual conflict of interest of persons who have a role in the design, 
conduct, analysis, publication, or any aspect of this trial  will be disclosed and managed . Furthermore, 
persons who have a perceived conflict of interest will be required to have such conflicts managed in a way 
that is appropriate to their participation in the design and conduct of this t rial. The study leadership in 
conjunction with the NCCIH  has est ablished policies and procedures for all study group members to 
disclose all conflicts of interest and will establish a mechanism for the management of all reported 
dualities of interest.  
10.2 ADDITIONAL CONSIDERATIONS  
N/A 
 
10.3 ABBREVIATIONS AND SPECIAL TERMS  
 
AE Adverse Event  
ANOVA  Analysis of Variance  
CFR Code of Federal Regulations  
COC  Certificate of Confidentiality  
DSMB  Data Safety Monitoring Board  
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 25 EC Ethics Committee  
eCRF  Electronic Case Report Forms  
FDA Food and Drug Administration  
FDAAA  Food and Drug Administration Amendments Act of 2007  
fMRI  Functional Magnetic Resonance Imaging  
GCP Good Clinical Practice  
GLP Good Laboratory Practices  
GMP  Good Manufacturing Practices  
HIPAA  Health Insurance Portability and Accountability Act  
IBMT  Integrative Body Mind Training  
ICH International Council  on Harmonisation   
IRB Institutional  Review Board  
ITT Intention -To-Treat  
NCT National Clinical Trial  
NIH  National Institutes of Health  
NIH IC  NIH Institute or Center  
OHRP  Office for Human Research Protections  
PI Principal Investigator  
QA Quality Assurance  
QC Quality Control  
RT Relaxation Training  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SOA Schedule of Activities  
SUD  Substance Use Disorder  
UP Unanticipated Problem  
US United States  
 
  
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 26 10.4 PROTOCOL  AMENDMENT  HISTORY  
The table below is intended to capture changes of IRB -approved versions of the protocol, including a 
description of the change and rationale. A Summary of Changes  table for the current amendment is 
located in the Protocol Title Page .  
 
Version  Date  Description of Change  Brief Rationale  
1.0 02/27/2019 Initial protocol  Initial protocol  
1.1 03/21/2020  Added  COVID screening  and updated 
subject payment  Modification  
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 27 11 REFERENCES  
 
1. McGinnis, J. M., Foege, W. H. (1999). Mortality and morbidity attributable to use of addictive substances in the 
United States. Proceedings of the Association of American Physicians. 111(2), 109 -118.  
2. Tang, Y. Y. (2017). The Neuroscience of Mindfulness Meditation: How the Body and Mind Work Together to 
Change Our Behavior? Springer Nature  
3. Tang, Y. Y., Ma, Y., Wang, J., Fan, Y., Feng, S., Lu, Q., Yu, Q., Sui, D., Rothbart, M. K., Fan, M., Posner, M. I. (2007).  
Short -term meditation training improves attention and self -regulation. Proceedings of the National Academy of 
Sciences, 104(43), 1 7152 -17156.  
4. Tang, Y. Y., Fan Y, Lu Q, Tan LH, Tang R, Kaplan R, Pinho, M.C., Thomas, B.P., Che K, Friston KJ, Reiman EM. 
(2020). Comparison of long -term physical exercise and meditation practice in an aging population. Frontiers in 
Psychology. 11:358  
5. Tang, Y. Y., Ma, Y., Fan, Y., Feng, H., Wang, J., Feng, S., Lu, Q., Hu, B., Lin, Y., Li, J., Zhang, Y., Wang, Y., Zhou, L. , 
Fan, M. (2009). Central and autonomic nervous system interaction is altered by short -term meditation. 
Proceedings of the National  Academy of Sciences, 106(22), 8865 -8870.  
6. Tang, Y. Y., Tang R, Gross JJ. (2019). Promoting emotional well -being through an evidence -based mindfulness 
training program. Frontiers in Human Neuroscience. 13:237  
7. Tang, Y. Y., Holzel , B.K., Posner, M.I. (2015). The neuroscience of mindfulness meditation. Nature Reviews 
Neuroscience, 16(4), 213 -225  
8. Tang, Y. Y., Lu, Q., Geng, X., Stein, E. A., Yang, Y., Posner, M. I. (2010). Short -term meditation induces white 
matter changes in the anterior cingulate. Proceedings of the National Academy of Sciences, 107(35), 15649 -15652.  
9. Tang, Y. Y., Lu, Q., Fan, M., Yang, Y., Posner, M. I. (2012). Mechanisms of white matter changes induced by 
meditation. Proceedings of the National Academy of Sciences, 109(26), 10570 -10574.  
10. Tang, Y. Y., Tang Y, Tang R, Lewis -Peacock J. (2017). Brief mental training reorganizes large -scale networks. 
Frontiers in Systems Neuroscience, 11:6  
11. Tang, Y. Y., Tang, R., Posner, M. I. (2013). Brief meditation training induces smoking reduction. Proceedings of 
the National Academy of Sciences, 110(34), 13971 -13975.  
12. Tang, Y. Y., Lu Q, Feng H, Tang R, Posner MI. (2015). Short -term meditation increases blood flow in anterior 
cingulate cortex and insula. Frontiers in Psychology, 6:212.  
13. Tang, Y. Y., Yang, L., Leve, L. D., Harold, G. T. (2012). Improving executive function and its neurobiological 
mechanisms through a mindfulness ‐based intervention: Advances within the field of developmental 
neuroscience. Child development perspective s, 6(4), 361 -366.14) Tang, Y. Y. (2009). Exploring the brain, 
optimizing the life. Beijing: Science Press.  
14. Tang, Y. Y. (2017). Brain -Based Learning and Education: Principle and Practice. Academic Press, 
Elsevier  
15. Tang, Y. Y., Tang R. (2020). The Neuroscience of Meditation: Understanding Individual Differences. 
Academic Press, Elsevier  
16. Tang, Y. Y., Posner, M. I. (2009). Attention training and attention state training. Trends in cognitive 
sciences, 13(5), 222 -227.  
17. Fan, Y., Tang, Y. Y., Tang, R., Posner, M.I. (2014). Short term integrative meditation improves resting 
alpha activity and Stroop performance. Applied Psychophysiology and Biofeedback, 39(3 -4), 213 -7. 
18. Fan, Y., Tang, Y. Y., Tang, R., Posner, M.I. (2015). Time course of conflict processing modulated by 
brief meditation training. Frontiers in Psychology, 6: 911  
19. Ding, X., Tang, Y. Y., Cao, C., Deng, Y., Wang, Y., Xin, X., Posner, M.I. (2015). Short -term meditation 
modulates brain activity of insight evoked with solution cue. Social Cognitive and Affective 
Neuroscience, 10(1), 43 -9. 
20. Ding, X., Tang, Y. Y., Tang, R., Posner, M.I. (2014). Improving creativity performance by short -term 
meditation. Behavioral and Brain Functions, 10:9  
21. Ding, X., Tang, Y. Y., Deng, Y., Tang, R., Posner, M.I. (2015). Mood and personality predict 
improvement in creativity due to meditation training. Learning and Individual Differences, 37, 217 -221 
Brain Mechanisms of Reducing Polysubstance Use   Version 1. 1  
Protocol 032 12020  21 March 202 0 
 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 28 22. Fan, Y., Tang, Y. Y., Posner, M. I. (2014). Cortisol level modulated by integrative meditation in a dose ‐
dependent fashion. Stress and Health, 30(1), 65 -70. 
23. Fan, Y., Tang, Y. Y., Ma, Y., Posner, M.I. (2010). Mucosal immunity modulated by integrative meditation in a 
dose dependent fashion. J Altern Complement Med. 16(2):151 -5 
24. Tang, Y. Y., Posner, M. I., Rothbart, M. K., Volkow, N. D. (2015). Circuitry of self -control and its role in reducing 
addiction. Trends in cognitive sciences, 19(8), 439 -444.  
25. Xue S, Tang, Y. Y., Tang R, Posner MI. (2014). Short -term meditation induces changes in brain resting EEG theta 
networks. Brain and Cognition, 87, 1 -6.  
26. Xue S, Tang, Y. Y., Posner MI. (2011). Short -term meditation increases network efficiency of the anterior 
cingulate cortex. NeuroReport, 22(12): 570 -4 
27. Tang, Y. Y., Rothbart, M. K., Posner, M. I. (2012). Neural correlates of establishing, maintaining, and switching 
brain states. Trends in cognitive sciences, 16(6), 330 -337.  
28. Tang, Y. Y., Posner MI. (2014). Training brain networks and states. Trends in Cognitive Sciences, 18(7):345 -50  
29. Tang, Y. Y., Tang, R., Posner, M. I. (2016). Mindfulness meditation improves emotion regulation and reduces 
drug abuse. Drug and alcohol dependence, 163, S13 -S18.  
30. Fan, Y., Cui , Y., Tang , R., Sarkar , A., Mehta , P., Tang, Y. Y.  (2024 ). Salivary testosterone and cortisol response to 
stress modulated by short -term meditation. Stress.  27:2316041.  
31. Baler, R. D., Volkow, N. D. (2006). Drug addiction: the neurobiology of disrupted self -control. Trends in 
molecular medicine, 12(12), 559 -566.  
32. Posner, M. I., Rothbart, M. K., Sheese, B. E., Tang, Y. (2007). The anterior cingulate gyrus and the mechanism of 
self-regulation. Cognitive, Affective, Behavioral Neuroscience, 7(4), 391 -395.  
33. Kelley, W. M., Wagner, D. D., Heatherton, T. F. (2015). In search of a human self -regulation system. Annual 
review of neuroscience, 38, 389 -411.  
34. Goldstein, R. Z., Volkow, N. D. (2011). Dysfunction of the prefrontal cortex in addiction: neuroimaging findings 
and clinical implications. Nature reviews neuroscience, 12(11), 652 -669.  
35. Bowen, S., Witkiewitz, K., Dillworth, T. M., Chawla, N., Simpson, T. L., Ostafin, B. D., Larimer, M. E., Blume, A. 
W., Parks, G. A., Marlatt, G. A. (2006). Mindfulness meditation and substance use in an incarcerated population. 
Psychology of addictive behaviors, 20(3), 343 -347.  
36. Bowen, S., Witkiewitz, K., Clifasefi, S. L., Grow, J., Chawla, N., Hsu, S. H., Carroll, H. A., Harrop, E., Collins, S. E., 
Lustyk, K. M., Larimer, M. E. (2014). Relative efficacy of mindfulness -based relapse prevention, standard relapse 
prevention, and tre atment as usual for substance use disorders: a randomized clinical trial. JAMA psychiatry, 71(5), 
547-556.  
37. Black, D. S. (2012). Mindfulness and substance use intervention. Substance use & misuse, 47(3), 199 -201.  
38. Chiesa, A., Serretti, A. (2014). Are mindfulness -based interventions effective for substance use disorders? A 
systematic review of the evidence. Substance use & misuse, 49(5), 492 -512.  
39. Zgierska, A., Rabago, D., Chawla, N., Kushner, K., Koehler, R., Marlatt, A. (2009). Mindfulness meditation for 
substance use disorders: a systematic review. Substance Abuse, 30(4), 266 -294.  
40. Khoury, B., Lecomte, T., Fortin, G., Masse, M., Therien, P., Bouchard, V., Chapleau, M., Paquin, K. , Hofmann, S. 
G. (2013). Mindfulness -based therapy: a comprehensive meta -analysis. Clinical psychology review, 33(6), 763 -771.  
41. Cheetham, A., Allen, N. B., Whittle, S., Simmons, J., Yücel, M., Lubman, D. I. (2014). Volumetric differences in 
the anterior cingulate cortex prospectively predict alcohol -related problems in adolescence. Psychopharmacology, 
231(8), 1731 -1742.  
42. Xiao, P., Dai, Z., Zhong, J., Zhu, Y., Shi, H., Pan, P. (2015). Regional gray matter deficits in alcohol dependence: a 
meta -analysis of voxel -based morphometry studies. Drug & Alcohol Dependence, 153, 22 -28. 
12 ATTACHMENT   
 
 
 
 
Dear Participant : 
 
The funded ''Brain mechanisms of reducing polysubstance use following a novel body -mind intervention '' study is 
seeking your part icipation to understand  brain mechanisms and training effects in those  who may use alcohol, 
tobacco , or cannabi s. The study will enable us to examine the potential mechanisms of meditation training and 
its effects on behavior al changes . 
 
What would I do if I participate?  
You will first take online questionnaires  and interviews for qualifying the study , then you sit down a chair 
comfortably while receiving meditation and /or neurofeedback  training . Prior to training , we will measure behavior 
via self -reports and simple physiological indexes such as breath rate  or heart rate to reflect your states such as 
alert and sleepy using non -invasive portable equipment. We will measure brain activity using non -invasive and 
widely used fMRI  (3 scans about 60 min each ). This procedure is well -defined in the extant literature. The 
respective time for the first and last visit will be approximately 50-60 min. Without measurements, you will receive  10 
sessions of training lasting approximately 60 minutes each. The total study is  expected to take about  15 hours . 
 
How will I benefit from participating?  
We would like to show our appreciation for your participation by giving you up to $ 300 in total after completion. If  
you do not complete the study, the payment will be prorated based on the time of task completed. You can also 
learn valuable information about how training may affect performance and behavior.  
 
Can I quit if I become uncomfortable?  
Your participation is completely voluntary, and you can choose to end the session at any time without penalty. 
While you will not receive the full incentive if you do not complete the study, you will receive a prorated incentive 
based on the time of task completed.  We will use all available data unless you indicate otherwise. Because of the 
enclosed space, a few  people become uncomfortable or anxious. If this happens to you, we will  stop immediately .  
  
What are the risks and/or discomforts to me if I join this study?  
There is very little risk to you for participation in this study. Many individuals report experiencing relaxation and 
calmness . As part of the fMRI scan, y ou will be continuously monitored throughout the scan.  If you have a 
pacemaker or some metal objects in your body, you will not be allowed to be in this study because of the strong 
magnet fields in the MRI scanner. Another risk is the possibility of metal objects being pulled into the magnet and 
potentially hitting you. To eliminate this risk, you will need to remove anything metal from your clothes, any metal 
piercings, and anything metal from your pockets. You will also walk through a metal detector (like airport 
scanners) when you come into the magnet chamber. It is important to know that no metal can be brought into the 
magnet room at any time. Once you are in the scanner, the door to the room will be closed so that no metal from 
outside accidentally goes near the magnet.    
  
How are you protecting privacy? 
Any information gathered for our study will remain confidential, and published reports will not mention individuals. 
Your file will be given a code number that will be used for identification, rather than a name. Only staff members 
working on this project have access, which will be used strictly for research purposes. The data collected, without 
any personally identifiable information, may be used in other research studying the effects of training in 
collaboration with this study. Any data that may be published in scientific journals will not reveal the identity of the 
participants.  
 
I have some question s about  this study.  Who  can I ask?  
If you have any questions about the research, please call or write to  Dr. Yi-Yuan Tang at  yiyuan.tang@ttu.edu ; 
806-742-3711 . If you have any questions about your rights as a participant, or in the event of a research -related 
problem or concern, please contact  TTU Human Research Protection at 806 -742-2064 .  
 
Your signature below indicates that you have read and understood the information provided above; that you willingly 
agree to participate; that you may withdraw your consent and discontinue participation at any time without penalty.  
 
Participant  Name __________________________________________            Date_________________  
 
 
Participant Signature _____________________________________________  